Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00575861 · ClinicalTrials.gov registry record · Phase 4
Zileuton and Exhaled Nitric Oxide in Asthmatics
A Phase 4 study, sponsored by Gelb, Arthur F., M.D..
- Completed
- Registry status
- Phase 4
- Development phase
- 19
- Enrollment target
NCT00575861 is a Phase 4 study that has completed, run by Gelb, Arthur F., M.D.. The registered enrollment target is 19 participants.
The verdict
NCT00575861, a Phase 4 study, has completed, sponsored by Gelb, Arthur F., M.D..
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 19 participants
- Enrollment target
Study Summary
Evaluate the additive role of zileuton 600mg qid to clinically stable asthmatics on Advair 250/50 bid. Since asthma is an endogenous inflammatory disease there usually is increased total exhaled, bronchial and alveolar nitric oxide which are markers of eosinophilic driven pathways of inflammation. The addition of zileuton which is a leukotriene synthesis inhibitor by itself or together with inhaled corticosteroids should reduce nitric oxide gas exchange.
Interventions
- DRUG zileuton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2005-09 |
| Est. Completion | 2007-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00575861
The ClinicalTrials.gov registry entry for NCT00575861 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gelb, Arthur F., M.D., which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which zileuton is the first listed.
NCT00575861 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00575861 about?
NCT00575861 is a clinical study titled "Zileuton and Exhaled Nitric Oxide in Asthmatics". Evaluate the additive role of zileuton 600mg qid to clinically stable asthmatics on Advair 250/50 bid. Since asthma is an endogenous inflammatory disease there usually is increased total exhaled, bronchial and alveolar nitric oxide which are markers of eosinophilic driven pathways of inflammation. T...
What is the current status of trial NCT00575861?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 19 participants. The study started on 2005-09. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00575861?
The interventions under investigation include: zileuton (DRUG).
Who is sponsoring clinical trial NCT00575861?
This trial is sponsored by Gelb, Arthur F., M.D., which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.